The Prajs-Drimmer Institute
for the Development of
Anti-Degenerative Drugs
Established in 2007, the Prajs-Drimmer Institute has become a leading driver of innovation in neurodegenerative disease research, advancing both fundamental discovery and translational drug development.
The Institute has supported the training of more than 70 M.Sc. and Ph.D. students through competitive fellowships, cultivating the next generation of scientists in the field.
In parallel, it has strategically invested in cutting-edge research infrastructure, enabling high-impact, technology-driven investigations and strengthening institutional capacity for breakthrough therapeutic development.
About Us
Our Mission
The Prajs-Drimmer Institute for the Development of Anti-Degenerative Drugs is dedicated to transforming the therapeutic landscape of neurodegenerative disorders through rigorous, innovation-driven research and translational drug development.
Our mission is to accelerate the discovery, validation, and clinical advancement of disease-modifying therapies by integrating cutting-edge technologies, mechanistic biology, and precision medicine approaches.
By fostering interdisciplinary collaboration and scientific excellence, we aim not only to improve treatment outcomes, but to redefine standards of care and fundamentally alter the trajectory of degenerative diseases.